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Abstract
Vitamin D regulates bone metabolism but has also immunoregulatory properties. In HIV-infected patients bone
disorders are increasingly observed. Furthermore, low 1,25(OH)2D3 levels have been associated with low CD4
counts, immunological hyperactivity, and AIDS progression rates. Few studies have examined the vitamin D
status in HIV-infected patients. This study will specifically focus on the effects of antiretroviral agents on vit-
amin D status. Furthermore, the effect of vitamin D status on CD4 cell recovery after initiation of HAART will
be evaluated. Among 252 included patients the prevalence of vitamin D deficiency (35 nmol/liter from April
to September and 25 nmol/liter from October to March) was 29%. Female sex, younger age, dark skin, and
NNRTI treatment were significant risk factors in univariate analysis, although in multivariate analyses skin
pigmentation remained the only independent risk factor. Median 25(OH)D3 levels were significantly lower in
white NNRTI-treated patients [54.5(27.9–73.8) nmol/liter] compared to white PI-treated patients [77.3
(46.6–100.0) nmol/liter, p  0.007], while among nonwhites no difference was observed. Both PI- and NNRTI-
treated patients had significantly higher blood PTH levels than patients without treatment. Moreover, NNRTI
treatment puts patients at risk of elevated PTH levels (6.5 pmol/liter). Linear regression analysis showed that
vitamin D status did not affect CD4 cell recovery after initiation of HAART. In conclusion, 29% of the HIV-1-
infected patients had vitamin D deficiency, with skin color as an independent risk factor. NNRTI treatment
may add more risk for vitamin D deficiency. Both PI- and NNRTI-treated patients showed higher PTH levels
and might therefore be at risk of bone problems. Evaluation of 25(OH)D3 and PTH levels, especially in NNRTI-
treated and dark skinned HIV-1-infected patients, is necessary to detect and treat vitamin D deficiency early.
1375
Introduction
VITAMIN D IS REQUIRED for bone health and calcium ho-meostasis and has important immunoregulatory prop-
erties. In HIV-infected patients bone disorders, like osteope-
nia and osteoporosis, are increasingly observed.1,2
Furthermore, low 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]
levels and polymorphisms in vitamin D receptor have been
associated with low CD4 counts, immunological hyperac-
tivity, and AIDS progression rates.3–6 However, only a few
studies have examined the vitamin D status in HIV-infected
patients (as recently reviewed7).
Plasma concentrations of 25-hydroxyvitamin D3
[25(OH)D3] are the best indicator of vitamin D status.8 Vit-
amin D is obtained from the diet and produced in the skin
under the influence of sunlight. All reactions in vitamin D
metabolism are catalyzed by enzymes from the cytochrome
P450 (CYP450) enzyme system (Fig. 1). Previtamin D3 is 25-
hydroxylated in the liver to 25(OH)D3 and then 1-hydrox-
ylated in the kidney to 1,25(OH)2D3, the active metabolite.9
Inactivation of vitamin D metabolites occurs mainly by re-
nal 24-hydroxylation, which is stimulated by 1,25(OH)2D3
and high calcium.
Vitamin D deficiency can be caused by several factors. The
synthesis of previtamin D3 in the skin decreases with age
and skin pigmentation.8,10 Also low sunlight exposure, obe-
sity, and insufficient vitamin D intake are known risk fac-
tors for vitamin D deficiency.11,12 In HIV-infected patients,
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HIV itself might lead to low 1,25(OH)2D3 levels by inhibi-
tion of renal 1-hydroxylase, possibly induced by an in-
hibitory effect of tumor necrosis factor (TNF)-.5 Alterna-
tively, 1,25(OH)2D3 might be low due to utilization for
maturation and proliferation of T lymphocytes during HIV
infection.7 In addition, highly active antiretroviral therapy
(HAART) might interact with vitamin D metabolism: pro-
tease inhibitors (PIs) and nonnucleoside reverse transcrip-
tase inhibitors (NNRTIs) can, respectively, inhibit or induce
CYP450 enzymes. In vitro, PIs showed a strong inhibition of
1- and 25-hydroxylase activities, while showing mild inhi-
bition of 24-hydroxylase,13 which may in vivo result in low
1,25(OH)2D3 levels. Also other drugs such as antiepileptic
agents and tuberculostatics can lead to reduced vitamin D
levels and subsequent low bone mineral density by either in-
ducing or inhibiting CYP450.14–16
In this study, we examined the prevalence and causes of
vitamin D deficiency among HIV-1-infected patients in the
Netherlands. We examined, in particular, whether and
which antiretroviral agents interfere with vitamin D metab-
olism. Additionally, the effect of vitamin D status on CD4
T cell recovery after initiation of HAART has been investi-
gated.
Materials and Methods
Study subjects
From January 2006 to August 2006, a cross-sectional sur-
vey on vitamin D deficiency was done among 254 adult
HIV1-infected patients visiting the Radboud University Ni-
jmegen Medical Centre, The Netherlands. We excluded sub-
jects with pregnancy, renal disorders (serum creatinine 220
mol/liter), and hepatic disorders (ASAT 200 or ALAT
225 IU/liter). Two hundred and fifty-two patients (99.2%)
could be included. 
The study received approval by the local ethics commit-
tee and all subjects provided written informed consent.
Study design
During their routine visit the vitamin D status of the pa-
tients was screened. Blood samples were collected for mea-
surement of 25(OH)D3, intact parathyroid hormone (PTH),
serum calcium, phosphate, creatinine, albumin, alkaline
phosphatase, ASAT and ALAT, CD4 and CD8 cell counts,
and viral load (VL). Patients’ age, sex, weight, length, skin
color/ethnicity, duration and stage of HIV infection [ac-
cording to 1993 Centers for Disease Control (CDC) crite-
ria17], duration and kind of antiretroviral therapy, and
medications were collected from patients’ medical history
or the database of HIV monitoring foundation. BMI was
calculated as weight in kg/length2 (in meters) for each 
subject.
Laboratory measurements
25(OH)D3 was measured by high-pressure liquid chro-
matography (HPLC) with UV detection, after prior extrac-
tion on small SepPak columns. Tritiated 25(OH)D3, collected
from the HPLC system during passage of the UV peak, was
used to correct for procedural losses.
Serum intact PTH in the first 33 patients was measured
using the Advantage PTH-N kit (Nichols, San Juan Capis-
trano, CA) and in the last 219 patients using the ELSA-PTH
kit (CIS Bio International, Gif-sur-Yvette, France). The CIS
BIO assay was recalibrated on the Advantage assay to give
identical measurement results.
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FIG. 1. Vitamin D metabolism. 7-Dehydrocholesterol is, under influence of sunlight, in the skin converted to previtamin
D3, which is transported to the liver by vitamin D-binding protein, where it is 25-hydroxylated (CYP27A1) to 25(OH)D3.
25(OH)D3 is then 1-hydroxylated (CYP27B1) in the kidney to 1,25(OH)2D3, the active metabolite.9 Inactivation of vitamin
D metabolites occurs mainly by renal 24-hydroxylation, which is stimulated by 1,25(OH)2D3 and high calcium.
Serum calcium, phosphate, creatinine, albumin, alkaline
phosphatase, ASAT and ALAT, cholesterol, triglycerides,
and glucose were determined by automated standard labo-
ratory techniques. Corrected calcium was calculated as fol-
lows: (Calcium)  [0.025  (albumin)]  1.
CD4 and CD8 cell counts were determined by standard
flow cytometry (FACS Count System, Becton Dickinson). Vi-
ral load was measured with the Cobas Amplicor HIV-1 mon-
itor test, with a minimal detection threshold before January
2000 of 400 HIV-1 RNA copies/ml and after January 2000
of 40 HIV-1 RNA copies/ml.
Questionnaire
For further evaluation of risk factors associated with vit-
amin D deficiency an invalidated questionnaire on dietary
vitamin D intake, intake of vitamin D supplements, and av-
erage sunlight exposure (hours/day) was taken by face-to-
face interview. Two hundred and one patients (79.8%) par-
ticipated in this questionnaire. Data on dietary questions
were processed in a special developed spreadsheet (Mi-
crosoft Excel 2000) in order to calculate the daily vitamin D
intake. The mean dietary vitamin D intake per patient was
calculated by using the Dutch Food table 2004.18 The rec-
ommended daily intake (RDI) of vitamin D is 2.5 g for
people aged 18–50 years, 7.5 g for people 51–70 years,
and 12.5 g for people 70 years.18
Definition of vitamin D deficiency and elevated PTH levels
Vitamin D deficiency was defined as circulating plasma
25(OH)D3 levels 35 nmol/liter in April–September or 25
nmol/liter in October–March. These levels are corrected for
season, because sunlight radiation differs between summer
and winter and can thereby directly influence the levels of
vitamin D.
Elevated PTH levels were defined as serum intact PTH
6.5 pmol/liter.
Effects of vitamin D deficiency on CD4 cell recovery
For this part only patients receiving HAART for 24
weeks were included. Patients were excluded when preg-
nant during initiation of HAART. As HIV-1 can induce a de-
cline in CD4 cells only patients with undetectable HIV-1 vi-
ral loads, measured 24 weeks after the initiation of HAART,
were included. Also patients that had fewer than three CD4
measurements available for regression analysis were ex-
cluded. One hundred and five patients could be included.
CD4 cell counts and VL of included patients were retro-
spectively collected from the database of the HIV Monitor-
ing Foundation starting 8 weeks after initiation of HAART
for as long as the viral load remained undetectable. The first
8 weeks of CD4 cell recovery were excluded, because then
CD4 cells increased rapidly due to a release of memory CD4
cells trapped in the lymphoid tissue.19
Statistical analysis
Continuous variables are expressed as median (Q1–Q3)
and categorical variables as number of cases (percentage).
Continuous variables were compared by the Mann–Whitney
U test or Kruskal–Wallis test when appropriate. Frequencies
were compared by the 2 test or Fishers’ exact test when ap-
propriate. Correlation between 25(OH)D3 levels and PTH
and CD4 cell count and low calcium and elevated PTH was
tested using Spearman correlation.
Logistic regression analysis was used to identify signifi-
cant risk factors for vitamin D deficiency. The following vari-
ables were entered: age, gender, BMI, skin color (white,
Mediterranean, Asian, or black), type of HAART (PI based,
NNRTI based, PI  NNRTI based, triple NRTI based, or no
HAART), vitamin D intake, and sunlight exposure.
For CD4 cell analysis, a linear regression line of the CD4
cell response to HAART was calculated for each individual
patient. The obtained slopes of each line represented the sec-
ond phase CD4 cell recovery rate of each patient. Because
CD4 cell recovery will probably stop around normal physi-
ological levels, with a lower limit of 500, the CD4 cell re-
covery rates for each patient were calculated until a recov-
ery of 500 and 600 cells was reached. Within these two
groups, median CD4 cell recovery rates were compared be-
tween the vitamin D-deficient group and patients with nor-
mal vitamin D levels using the Mann–Whitney U test. Also,
baseline CD4 cell values can influence the CD4 cell recovery
rate; therefore the patients were stratified according to their
baseline CD4 cell count in 0–200 and 200 CD4 cells and the
former comparison was reapplied.
All analyses were performed using SPSS statistical soft-
ware package release 14.0.2 (SPSS Software, Chicago, IL). A
p-value 	0.05 was considered statistically significant.
Results
Subject sample and characteristics
Overall, vitamin D status was determined for 254 patients.
Two patients were excluded because of pregnancy and HIV-
2 coinfection, respectively. Subsequently 252 patients could
be included. The population characteristics are summarized
in Table 1.
Prevalence and risk factors of vitamin D deficiency
Data for patients according to presence or absence of vit-
amin D deficiency are shown in Table 1. The prevalence of
vitamin D deficiency was 29.0% (73/252). Females had a sig-
nificantly higher prevalence of vitamin D deficiency (58.1%)
compared to males (24.7%) (p  0.010). The median (Q1–Q3)
25(OH)D3 levels were significantly lower in females, 32.25
(22.55–51.58) nmol/liter, compared to males, 56 (30–78.5)
nmol/liter (p  0.001). Postmenopausal females are at risk
of developing vitamin D deficiency and therefore we com-
pared the age of female patients with or without vitamin D
deficiency. The median age of females with vitamin D defi-
ciency was 36.5 (31.5–41.25) years and of females without vi-
tamin D deficiency was 35.5 (29.5–43.75) years; this differ-
ence was not statistically significant.
The prevalence of vitamin D deficiency was 19% in white,
33% in Mediterranean, 44% in Asian, and 62% in black pa-
tients. Black patients were at a significantly higher risk of de-
veloping vitamin D deficiency compared to the other groups
(OR 6.22, 95% 3.20–12.08). Median (Q1–Q3) serum levels of
25(OH)D3 in white, Mediterranean, Asian, and black patients
were 59.50 (36.20–82.75), 57.00 (22.75–64.00), 32.00 (21.50–
57.50), and 27.10 (16.75–36.95) nmol/liter, respectively; the
differences were statistically significant between white and
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black (p  0.001) and between Mediterranean and black pa-
tients (p  0.026). Nonwhite patients were significantly
younger [median(Q1–Q3): 34 (30–39.75) years] than whites
[45(39–53) years], which may explain the significantly
younger age of the vitamin D-deficient patients.
The prevalence of vitamin D deficiency was 24.5% in pa-
tients without treatment and 30% in patients receiving
HAART: 23.0% in patients who received PI-based HAART
and 36.5% in patients on NNRTI-based HAART. Prevalence
tended to be higher among NNRTI-treated patients com-
pared to PI-treated patients (p  0.070). Usage of NNRTIs
was of significant influence on vitamin D deficiency (OR 1.86,
95% CI 1.07–3.22). Median (IQR) 25(OH)D3 levels did not dif-
fer between patients with and without treatment [48.00
(27.00–76.00) vs. 50.3 (34.6–72.2), respectively, p  0.750].
Median (IQR) 25(OH)D3 levels were significantly lower for
NNRTI-treated patients [42.5 (22.25–67.80) nmol/liter] com-
pared to PI-treated patients [60.00 (29.00–89.20) nmol/liter,
p  0.017]. In Fig. 2 plasma 25(OH)D3 levels according to the
therapy groups stratified for white and nonwhite skin color
are shown. Within the white population the median
25(OH)D3 levels of PI-treated patients [77.30 (46.85–100.00)
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TABLE 1. PATIENT CHARACTERISTICS OF HIV-1 SEROPOSITIVE PATIENTS: 
OVERALL AND WITH AND WITHOUT VITAMIN D DEFICIENCYa
Vitamin D
deficient Normal vitamin D
Variables Overall (N  252) (N  73, 29%) (N  179, 71%) p valueb
Clinical data
Male sexc 190 (75.4) 47 (64.4) 143 (79.9) 0.001
Female sexc 62 (24.6) 26 (35.6) 36 (20.1) 0.001
Age (years)d 41.00 (35–50) 38.0 (32.0–46.5) 43.0 (37.0–52.0) 0.005
BMI (kg/m2)c 23.57 (21.6–25.7) 23.39 (21.51–25.60) 23.73 (21.64–26.02) 0.740
CD4 cell count (cells/ml)d 420 (290–600) 420 (310–560) 420 (280–625) 0.931
CD8 cell count (cells/ml)d 780 (580–1150) 670 (515–950) 860 (590–1205) 0.009
CD4/CD8 ratiod 0.54 (0.30–0.82) 0.62 (0.38–0.90) 0.51 (0.28–0.76) 0.055
VL (copies/ml)d 40 (40–400) 40 (40–500) 40 (40–400) 0.790
285 (136–518) 275 (116–516) 0.781
HIV stage (1993 CDC criteria)
Ac 126 (50) 39 (53.4) 87 (48.6) 0.786
Bc 52 (20.6) 14 (19.2) 38 (21.2) 0.001
Cc 74 (29.4) 20 (27.4) 54 (30.2) 0.001
Immune stage (1993 CDC criteria)
CD4  500 cells/mm3c 95 (37.7) 30 (41.1) 65 (36.5) 0.682
CD4 200–499 cells/mm3c 131 (52.0) 37 (50.7) 93 (52.2) 0.001
CD4  200 cells/mm3c 26 (10.3) 6 (8.2) 20 (11.2) 0.001
Skincolor
Whitec 184 (73) 35 (47.9) 149 (83.2) 0.001
Mediterraneanc 9 (3.6) 3 (4.1) 6 (3.4) 0.721
Asianc 9 (3.6) 4 (5.5) 5 (2.8) 0.287
Blackc 50 (19.8) 31 (42.5) 19 (10.6) 0.001
Antiretroviral treatment
No treatmentc 53 (21) 13 (17.8) 40 (22.3) 0.497
PI-based regimenc 61 (24.2) 14 (19.2) 47 (26.3) 0.260
NNRTI-based regimenc 104 (41.3) 38 (52.1) 66 (36.9) 0.034
PI- and NNRTI-based regimenc 11 (4.4) 2 (2.7) 9 (5.0) 0.518
Triple NRTI-based regimenc 23 (9.1) 6 (8.2) 17 (9.5) 1.000
HAART duration (weeks)d 238 (108–363) 264 (134–380) 213 (102–355) 0.236
Metabolic parameters
25-hydroxyvitamin D 49.00 (27.45–74.83) 20.4 (16–26.15) 62.00 (46.8–84.5) 0.001
(nmol/liter)d
Parathyroid hormone 4.1 (2.8–5.3) 5.1 (3.89–7.61) 3.57 (2.60–4.79) 0.001
(pmol/liter)d
Calcium (mmol/liter)d 2.34 (2.27–2.39) 2.30 (2.23–2.36) 2.36 (2.30–2.41) 0.001
Corrected calcium 2.32 (2.26–2.38) 2.29 (2.25–2.36) 2.33 (2.27–2.40) 0.022
(mmol/liter)d
Phosphate (mmol/liter)d 0.93 (0.82–1.08) 0.95 (0.81–1.08) 0.92 (0.83–1.09) 0.760
Albumin (g/liter)d 41 (38–43) 40 (38–42) 41.5 (39–44) 0.017
aBMI, body mass index; PI, protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcrip-
tase inhibitor; HAART, highly active antiretroviral therapy.
bp-value of comparison of prevalence or values between vitamin D-deficient patients and patients with normal vitamin D with Chi-square
test or Mann–Whitney U test, respectively.
cUnivariate analysis: data presented as N, %.
dUnivariate analysis: data presented as median (Q1–Q3).
nmol/liter] were significantly higher compared to NNRTI-
treated patients [54.50 (27.90–73.78) nmol/liter; p  0.007] or
no treatment groups [57.00 (68.00–78.35) nmol/liter; p 
0.049]. Interestingly, no significant differences in 25(OH)D3
levels were found among nonwhite patients treated with PI,
NNRTI, or without treatment [29.00 (20.40–57), 22.00
(14.70–38.40), and 33.3 (23.25–44.53) nmol/liter, respec-
tively].
In addition to female gender, younger age, lower CD8 cell
count, black skin color, and NNRTI treatment, higher PTH,
lower calcium, and lower albumin levels were also signifi-
cantly associated with vitamin D deficiency in univariate
analysis (Table 1).
Results of the questionnaire are shown in Table 2. There
was no significant difference in either dietary vitamin D in-
take or sunlight exposure between the two groups. Overall,
25.9% of the patients (52/201) used nonprescribed vitamin
D supplements, for example, multivitamins. Usage of a vit-
amin D supplement was not significantly different between
vitamin D-deficient and -nondeficient patients (p  0.532).
When the total intake of vitamin D from food and supple-
ments is considered, 55 patients (27.3%) consumed less than
the RDI. When patients consuming vitamin D supplements
were excluded, 54 patients (36.2%) consumed less than the
RDI. Again, no significant difference was found in percent-
age of subjects consuming less than the RDI between patients
with and without vitamin D deficiency [34.1% (n  14) and
37.0% (n  40), respectively; p  0.743].
Multiple logistic regression analysis was used to identify
significant risk factors for vitamin D deficiency in HIV-1-in-
fected persons. Because the food questionnaire was done in
only 201 patients, the multivariate analysis could be con-
ducted only for that population. Only skin color remained a
significant risk factor for vitamin D deficiency (AOR  5.4,
95% CI 2.3–12.2, p  0.001). After stratification of the popu-
lation into white and nonwhite groups no independent risk
factor for vitamin D deficiency remained.
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TABLE 2. QUESTIONNAIRE RESULTS OF HIV-1-INFECTED PATIENTS STRATIFIED FOR VITAMIN D DEFICIENCYa
Vitamin D deficient Normal vitamin D
(N  53, 26%) (N  148, 74%) p valueb
Supplement
Use of Vit D supplementc 12 (22.6) 40 (27.0) 0.532
Vit D supplement intake 5.00 (5.00–5.00) 5.00 (5.00–5.00) 0.311
(g/day)d
Diet
Dietary Vit D intake 4.3 (2.7–5.5) 4.5 (3.1–6.3) 0.143
(g/day)d
Total Vit D intake (g/day)d 4.64 (2.83–7.30) 5.57 (3.7–7.98) 0.131
Total Vit D intake  RDIc 14 (26.4) 41 (27.7) 0.857
Total Vit D intake  RDIc 39 (73.6) 107 (72.3)
Sunlight
Sunlight exposure 60 (30–150) 90 (60–180) 0.168
(min/day)d
aVit D, vitamin D; RDI, recommended daily intake.
bp-value of comparison of prevalence or values with Chi-square test or Mann-Whitney U test, respectively.
cN, %.
dMedian (Q1–Q3).
FIG. 2. Plasma 25-hydroxyvitamin D3 levels for white and
nonwhite patients in the different therapy groups. Box plots
show the median (horizontal line in the center of each box),
the 25th and 75th percentiles (bottom and top of each box),
and the 10th and 90th percentiles (bottom and top of error
bars). Plasma 25(OH)D3 levels differed significantly only
within the white group for PI-treated patients compared to
NNRTI-treated patients (*p  0.007) and patients that re-
ceived no treatment (**p  0.049).
Prevalence of elevated PTH levels and effect of HAART
For two patients (with normal vitamin D) the PTH levels
were missing. Overall, 42 patients (16.8%) had elevated PTH
levels. Among the patients with vitamin D deficiency, 27 pa-
tients (37%) had elevated PTH levels. No patients (0/13,
0.0%) without treatment, five patients (5/14, 35.7%) receiv-
ing PI-based HAART, and 19 patients (19/38, 50%) on
NNRTI-based HAART developed elevated PTH levels in ad-
dition to vitamin D deficiency. Patients treated with NNR-
TIs had a significantly higher risk of developing elevated
PTH levels in addition to vitamin D deficiency (OR 3.93, 95%
CI 1.65–9.37).
Among the patients with normal vitamin D levels, 15
(15/177, 8.5%) patients developed elevated PTH levels; one
patient (1/39, 2.6%) had no treatment, four patients (4/47,
8.5%) received PI-based HAART, and nine patients (9/65,
13.8%) received NNRTI-based HAART. There was no sig-
nificant difference in prevalence of elevated PTH levels
among these treatment groups (p  0.212). In Fig. 3, the PTH
levels of patients without and with PI or NNRTI treatment
according to 25(OH)D3 levels are shown. The upper left
quadrant, with low vitamin D3 and high PTH blood levels,
shows an overrepresentation of NNRTI- and PI-treated pa-
tients.
There was a significant inverse correlation between serum
PTH and 25(OH)D3 levels (r  –0.394, p  0.001). PTH lev-
els of patients on PI treatment [4.27 (3.26–5.46) pmol/liter]
or NNRTI treatment [4.61 (3.30–6.89) pmol/liter] were 
significantly higher than patients without treatment [2.98
(2.15–3.68) pmol/liter; p  0.001 and 0.001, respectively].
The PTH levels of patients on NNRTIs were nonsignificantly
higher than that of patients on PI treatment (p  0.098).
There is a significant relationship between low calcium
levels and elevated PTH (r  0.153 p  0.031).
Effects of vitamin D deficiency on CD4 cell recovery
One hundred and five patients could be included in re-
gression analysis with CD4 cell counts up to 500 cells, 31 pa-
tients (29.5%) had vitamin D deficiency, and 74 patients
(70.5%) had normal vitamin D levels. There was no signifi-
cant difference in median CD4 cell recovery rates between
patients with and without vitamin D deficiency [median
(IQR) 1.17 (0.69–2.91) and 1.10 (0.29–2.25), respectively; p 
0.177]. Also with a cutoff of 600 CD4 cells/ml no statistical
differences in CD4 cell recovery rates were found.
In addition, when patients were stratified according to
their baseline CD4 cell count, no statistically significant dif-
ferences in CD4 cell recovery rate were found (data not
shown). Overall, there was no significant correlation be-
tween CD4 cell counts and 25(OH)D3 levels (r  0.059, p 
0.351).
Discussion
We found a prevalence of 29% vitamin D deficiency
among HIV1-infected patients. In univariate analysis, female
sex, dark skin color, younger age, and NNRTI treatment
were found to be significant contributors. Skin color re-
mained the only independent risk factor for vitamin D defi-
ciency in multivariate analysis.
The 25(OH)D3 levels were significantly lower among
NNRTI-treated patients as compared to PI-treated patients.
When the group was stratified into whites and nonwhites,
the 25(OH)D3 levels remained significantly lower for white
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FIG. 3. PTH levels of patients with NNRTI-based, PI-based, or no antiretroviral treatment according to serum 25(OH)D3
levels (nmol/liter). Reference lines show low vitamin D levels (35 nmol/liter) and elevated PTH levels (6.5 pmol/liter).
In the upper left corner patients with elevated PTH levels and vitamin D deficiency can be found.
NNRTI-treated patients compared to white PI-treated pa-
tients, while among the nonwhites no significant differences
were found. These results suggest that NNRTI treatment
may have increased the risk for vitamin D deficiency. Inter-
estingly, NNRTI- as well as PI-treated patients had higher
levels of PTH compared to patients without treatment. More-
over, NNRTI treatment puts patients at risk for elevated PTH
levels. No effect of vitamin D status on CD4 recovery rate
after initiation of HAART was found.
Vitamin D deficiency among HIV-infected patients has
previously been reported in only two studies.20,21 Kuehn et
al. found a prevalence of 50% vitamin D deficiency (50
nmol/liter) among 21 HIV-infected patients with advanced
AIDS and hypocalcemia.21 Coodly et al. found 17% vitamin
D deficiency [average 25(OH)D-2SD] among adult HIV-in-
fected patients.20 These results cannot easily be compared
with our study as the study populations are small, the pa-
tients also had hypocalcaemia, and different definitions of
25(OH)D deficiency were used. Whether the incidence of vi-
tamin D deficiency in our study population is high can, how-
ever, not be firmly concluded, as we lack an HIV-negative
control group. Also in the literature there are no other re-
ports that compared vitamin D status between HIV-positive
and HIV-negative controls. One study by Teichmann et al.
reported that 25(OH)D levels were significantly lower in
HIV-positive compared to HIV-negative individuals.6
In univariate analysis female sex, pigmented skin, younger
age, and NNRTI treatment were significant contributors to
the prevalence of vitamin D deficiency in our patient popu-
lation. In the study by Teichmann et al., lower 25(OH)D3 lev-
els were found among females compared to males; however
no information on the prevalence of vitamin D deficiency
was given.6 In the literature the prevalence of vitamin D de-
ficiency among adult HIV-negative females in Europe
ranged from 26% to 80%, with causes being menopausal or
veiling traditions.22,23 In our study, the median age of fe-
males was younger than 50 years and showed no differences
between patients with and without vitamin D deficiency.
None of the females in the present study wore a veil.
Skin pigmentation is a known contributor to the develop-
ment of vitamin D deficiency.8 A study by Grootjans-Geerts
reported high levels of vitamin D deficiency among non-
western immigrants in the Netherlands.24 The younger age
of black patients in this study contributed to the significantly
younger age of the vitamin D-deficient group. As a conse-
quence, in multivariate analysis only skin pigmentation re-
mained a significant risk factor for vitamin D deficiency.
Although HAART was no significant contributor for vit-
amin D deficiency in multivariate analysis, our results sug-
gest that antiretroviral agents may affect 25(OH)D3 levels.
At first sight, we found no significant differences in
25(OH)D3 levels between patients with and without anti-
retroviral therapy. In contrast, Ramayo et al. found signifi-
cantly lower 25(OH)D3 levels among naive compared to
HAART-treated HIV-infected patients. This was most likely
caused by undernourishment associated with HIV disease
progression, given the fact that lower albumin levels were
found among naive patients.25 We specifically then looked
at the effects of PIs and NNRTIs on 25(OH)D levels, after
correction for skin color, and found among whites signifi-
cantly lower 25(OH)D3 levels in patients treated with NNR-
TIs compared to PI-treated patients. Furthermore, NNRTI-
treated patients had significantly higher PTH levels com-
pared to patients without treatment. The low vitamin D lev-
els may have been caused by increased catabolism of
25(OH)D3 or 1,25(OH)2D3 through induction of CYP450 by
NNRTIs.
On the other hand, we found that white PI-treated per-
sons had significantly higher 25(OH)D3 levels compared to
white NNRTI-treated patients and white patients without
treatment. In vitro, PIs have been found to inhibit 1-hy-
droxylation of 25(OH)D3 to 1,25(OH)2D3.13 This may explain
the elevated PTH levels that were found in our study. In 
addition, Madeddu et al. reported significantly lower
1,25(OH)2D3 levels within all HIV-infected patients com-
pared to controls, with the lowest levels found among PI-
treated patients.26
Within the nonwhite population no significant differences
in 25(OH)D3 levels were found, which emphasizes the great
contribution of skin pigmentation in vitamin D deficiency.
Low 1,25(OH)2D3 levels have been associated with low
CD4 counts.3–6 However, in the present study and in that
of Teichmann et al., no associations between 25(OH)D3 lev-
els and CD4 cells were found.6 Also no differences in CD4
recovery rates after initiation of HAART between patients
with and without vitamin deficiency were found.
This is the first study evaluating the prevalence of vitamin
D deficiency among a large cohort of adult HIV-1-infected
patients. One drawback of the present study is the lack of an
HIV-negative control group, which limits firm conclusions
on incidence levels in HIV-infected patients. Nevertheless,
this is the first study evaluating the effect of antiretroviral
therapy on vitamin D status. In the present study it was
shown that NNRTI-treated patients may be at risk for vita-
min D deficiency. Both PI- and NNRTI-treated patients
showed higher PTH levels and might therefore be at risk for
increased bone mass loss.
An adequate vitamin D status is necessary for the main-
tenance of good bone mineral density. Therefore the vitamin
D status of HIV-infected patients, especially those having
dark skin color or receiving NNRTI- or PI-containing
HAART, should be evaluated by measuring 25(OH)D3 and
PTH levels. By doing so vitamin D deficiency could be de-
tected early and treated.
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